Continuing Medical Education Conference Coverage CROI 2020

CROI 2020 - 2 Banner v2  

 

CROI-2020-2_OnDemandweb-button 
   

About the Program:

Program Overview:

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 27th Conference on Retroviruses and Opportunistic Infections (CROI 2020). This program consists of four components: (1) From Conference to Clinic: Reviewing and Applying Data from CROI 2020: a case-based on-line webcast featuring expert faculty reviewing key presentations with a focus on clinical management and treatment; (2) CME Internet Symposium: CROI 2020 Expert Review:* a 1.5-hour Internet symposium that features an overview of key presentations and posters, selected by the expert faculty; (3) Rapid-Fire Review of CROI 2020:* a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) CROI 2020 e-Newsletter: a brief on-line summary of the most essential data presented at the conference.

The CME Internet Symposium: From Conference to Clinic: Reviewing and Applying Data from CROI 2020 will feature a panel of HIV experts reviewing key presentations on antiretroviral therapy presented at CROI 2020. The review will include several clinical cases focusing on HIV therapeutic options and developments, including: current treatment and management strategies; algorithms and recommendations; therapies in development; epidemiology, diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All on-line components of the program can be accessed at www.viraled.com.

This program is jointly provided by the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc. in collaboration with Postgraduate Institute for Medicine. It is not a session created by or presented at CROI 2020 and it is not sanctioned by the organizers of CROI 2020.

*These components are produced by the Postgraduate Institute for Medicine and ViralEd, Inc and supported by an independent educational grant from Gilead Sciences Medical Affairs.

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Explain the epidemiology of HIV today
  • Initiate ARV therapy rapidly following an HIV diagnosis
  • Select optimal ARV therapy to all people with HIV infection
  • Identify the risk and causes of ARV resistance and learn how to reduce this risk through appropriate ARV regimen selection
  • Assess the impact of ARV adverse events on treatment success and be able to adjust ARV regimens to maximize tolerability
  • Recognize ARV adverse effects, especially neuropsychiatric effects and weight gain,and adjust ARV regimens to minimize these effects
  • Recognize mental health issues, such as stress, anxiety, depression, and substance use, in patients being treated for HIV infection, and employ approaches for addressing these mental health issues

Release Date: April 2, 2020

Expiration Date: April 2, 2021

Estimated time to complete the program: 15-30 minutes per module

Media: Internet

Back to Top

Faculty:

José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany
Boston, Massachusetts

Marta Boffito, MD, PhD
St. Stephen's AIDS Trust and Imperial College
Chelsea and Westminster Hospital
London, United Kingdom

Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

 

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
 
Back to Top

Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

For Each Program Module:

Case Studies in Prevention Module:
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Case Studies in Treatment-Naive Patients Module:
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Studies in Treatment-Experienced Patients Module: 
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Studies in Hepatitis and HIV Co-infections Module:
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Studies in Pharmacology Module:
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case Studies on Adverse Events and Co-morbidities Module: 
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to The Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jose Arribas, MD

  • Consulting Fees:Janssen, MSD,ViiV, Alexa, Teva

Marta Boffito, MD

  • Consulting Fees: Gilead, BMS, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Gilead, Janssen, ViiV, BMS
  • Contracted Research: Gilead, Janssen, ViiV, BMS

Ian Frank, MD

  • Consulting Fees: Gilead, GSK
  • Contracted Research: Johnson & Johnson

Graeme Moyle, MD

  • Consulting Fees: Theratechnologies, Gilead, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Theratechnologies, Gilead, ViiV
  • Contracted Research (institution only): Amgen, Merck, Gilead, ViiV

Jürgen Rockstroh, MD

  • Consulting Fees: Gilead, Merck, Janssen, Theratechnologies, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): AGilead, Merck, Janssen, ViiV

Paul Sax, MD

  • Consulting Fees: Gilead, GSK/ViiV, Janssen, Merck
  • Contracted Research: Gilead, GSK/ViiV, Merck
  • Other (Editorial Boards): Medscape, UpToDate, NEJM Journal Watch, Open Forum ID

Renslow Sherer, MD

  • Nothing to Disclose

Annenberg Center for the Health Sciences at Eisenhower staff involved in this activity have no relevant commercial relationships to disclose.

The PIM planners and managers have nothing to disclose.

The ViralEd planners and managers have nothing to disclose. 

Back to Top

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity.  During the period, April 2, 2020 through April 2, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment of completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 15286. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigationaluses of agents that are not indicated by the FDA. The planners of this activitydo not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and donot necessarily represent the views of the planners.  Please refer to theofficial prescribing information for each product for discussion of approvedindications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

 

Back to Top

Computer System Requirements

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player. 

 

Back to Top

 

 

PIM_small          Annenberg Center For Health Science logo

VE logo 300px

 

This activity is supported by an independent educational grant from Janssen Therapeutics, Division of Janssen Products LP.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.


Prepare to print

Share this page:

Get link code to this page     


Back to Top